FOXO3 and cancer: Although there is no publicly available preclinical evidence, it might be extrapolated from this finding that KRAS G12C inhibitors may sensitize KRAS G12C-mutated cancers to PARP inhibitors by suppressing the RAS/MAPK pathway and increasing FOXO3a expression.